Could a diabetes drug also protect the brain? new trial aims to find out
NCT ID NCT07083154
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This 76-week study tests whether mazdutide, a weekly injection already used for diabetes, can slow memory and thinking decline in 420 adults aged 50-75 with type 2 diabetes and early dementia. Half receive the drug, half a placebo. Researchers will measure changes in thinking skills and daily function over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mazdutide (a weekly injection that targets two gut hormones to control blood sugar and possibly protect the brain)
What this could lead to
If it works, this could point toward a new treatment that slows memory loss and thinking problems in people with type 2 diabetes and early dementia.
What could go wrong
This is a Phase 3 trial, but it's still experimental. The drug may not improve cognition, and side effects like nausea or digestive issues are possible. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Endocrinology, Changzhou No.2 People's Hospital
RECRUITINGChangzhou, Jiangsu, China
Contact
Contact
Contact
-
Department of Endocrinology, Endocrine and Metabolic Disease Medical Center,Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
RECRUITINGNanjing, Jiangsu, 210008, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Department of Endocrinology, Huadong Hospital Affiliated to Fudan University
RECRUITINGShanghai, 200040, China
Contact
Contact
Contact
-
Department of Endocrinology, Jiangsu Province Hospital of Traditional Chinese Medicine
RECRUITINGNanjing, Jiangsu, China
Contact
Contact
-
Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University
RECRUITINGNanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Department of Endocrinology, Shanghai General Hospital
RECRUITINGShanghai, Shanghai Municipality, 200080, China
Contact
Contact
-
Department of Endocrinology, Xiangya Hospital of Central South University
NOT_YET_RECRUITINGChangsha, Hunan, 410008, China
Contact
Contact
-
The Second Affiliated Hospital of Dalian Medical University
NOT_YET_RECRUITINGDalian, Liaoning, China
Contact
Contact